Business Wire

CA-THE-OPEN-GROUP

6.1.2022 10:02:04 CET | Business Wire | Press release

Share
Energistics Becomes an Affiliate of The Open Group® Following Completion of Governance Transition

Effective January 1st, Energistics Consortium, Inc. is now an affiliate of The Open Group®, a global consortium that enables the achievement of business objectives through technology standards. Energistics remains a separate entity, with The Open Group assuming control of Energistics operations, in a move which will enable broader community access, more efficient collaboration, and stronger standards evolution in line with the global energy transition.

Having proudly served the industry for over thirty years, Energistics is also a long-standing member of The Open Group OSDU™ Forum, and in October 2018 became the first non-operator company to be invited to join the Forum. Its WITSML , RESQML , PRODML , and ETP standards have become universal in the industry and form a critical component of the OSDU Data Platform.

Development will continue in Energistics Special Interest Groups (SIGs) to ensure the standards remain a vibrant part of the Energy community. Most recently, Energistics Transfer Protocol v1.2 was released in September 2021, and a consolidated Release Candidate for new versions of RESEQML, PRODML, and WITSML was made available in December 2021.

This work will support both the wider industry and the ongoing development of the OSDU Data Platform and standards for analyzing legacy subsurface energy data as well as new energy data from wind, geothermal, hydrogen, photovoltaic sources, and carbon capture, utilization, and storage data sources.

“As Energistics starts an exciting new chapter in its development, we want to thank the more than 3,500 upstream subject matter experts, from over 115 member companies, who have contributed to its development over the last thirty years,” said Ross Philo, CEO of Energistics. “We are also particularly grateful to our operational staff, who have served the industry with outstanding dedication. They have ensured a smooth transition for our members, and we wish them all the best in their next adventure.”

Today’s transition of governance reflects the significant overlap between Energistics and The Open Group OSDU Forum, with 42 of the 220 current Forum members also being Energistics members. Retaining its own board, the work of Energistics will now be overseen by members of both organizations alongside The Open Group itself.

“The relationship between Energistics and The Open Group has been a long and fruitful one, and this is the right next step for our organizations,” adds Steve Nunn, CEO and President of The Open Group. “Bringing the knowledge and capabilities of The Open Group OSDU Forum and the Energistics SIGs closer together means that we will continue to lead the charge in data exchange standards for the industry, while also opening doors to a broader community for both organizations. We are committed to ensuring that the Energistics standards continue to evolve, thrive, and enable cross-discipline integration of industry data.”

- ENDS -

About Energistics

Energistics is the leading upstream oil and gas industry's data standards body. We are a global, non-profit consortium established over 30 years ago to bring together industry professionals in a neutral and collaborative environment to develop and deploy open data exchange standards and to address oil and gas information sharing challenges. Our members consist of international and nationalized oil companies, oilfield service companies, hardware and software vendors, system integrators, regulatory agencies, and the global standards user community. For more information, visit our website at www.energistics.org .

About The Open Group

The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 850 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. Further information on The Open Group can be found at www.opengroup.org .

About The Open Group OSDU Forum

The Open Group OSDU Forum is developing the Open-Source Software OSDU Data Platform and associated standards that enables the Energy industry to develop the transformational technology implementation to support the world's changing Energy needs. The Open Group OSDU Forum has over 225 member organizations and over 1900 subscribers worldwide. Membership in The Open Group OSDU Forum is available to all energy stakeholders including international and nationalized oil companies, new energy providers, application developers, service operators, technology providers, software companies, academia, and more. More information on the OSDU Forum can be found at www.osduforum.org .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye